Bernstein raised the firm’s price target on Regeneron (REGN) to $916 from $911 and keeps an Outperform rating on the shares ahead of quarterly results. For Eylea, Q4 results were already pre-announced, so the firm will be looking more toward management commentary on potential for further acceleration in HD launch, where it is bullish. For Dupixent, Bernstein is in-line on 4Q product sales and model a 2% beat on Sanofi (SNY) collaboration revenues.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron: Dupixent-Led Growth, EYLEA Franchise Stabilization, and High-Value Pipeline Catalysts Underpin Buy Rating
- The Week That Was, The Week Ahead: Macro and Markets, Jan. 25
- Regeneron price target raised to $875 from $750 at Evercore ISI
- Regeneron Explores New Intralesional Use for Libtayo in Skin Cancer: What Investors Should Know
- Regeneron Pharmaceuticals: Dupixent-Driven Growth Offset by Patent Uncertainty, Supporting a Hold Rating